• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study.

作者信息

Xavier Denis, Pais Prem, Sigamani Alben, Pogue Janice, Afzal Rizwan, Yusuf Salim

机构信息

Department of Pharmacology, St John's Medical College, Bangalore, India.

出版信息

Nat Clin Pract Cardiovasc Med. 2009 Feb;6(2):96-7. doi: 10.1038/ncpcardio1438. Epub 2008 Dec 23.

DOI:10.1038/ncpcardio1438
PMID:19104516
Abstract
摘要

相似文献

1
The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study.检验多效药丸背后理论的必要性：印度多效复方制剂研究的理论依据
Nat Clin Pract Cardiovasc Med. 2009 Feb;6(2):96-7. doi: 10.1038/ncpcardio1438. Epub 2008 Dec 23.
2
Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators.全剂量复方药丸（含钾）与低剂量复方药丸（复方制剂）对心血管疾病高危个体危险因素降低及耐受性的比较：第二次印度复方制剂研究（TIPS-2）研究者
Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):463-71. doi: 10.1161/CIRCOUTCOMES.111.963637. Epub 2012 Jul 10.
3
The International Polycap Study-3 (TIPS-3): Design, baseline characteristics and challenges in conduct.国际多中心前列腺癌研究-3（TIPS-3）：设计、基线特征和实施挑战。
Am Heart J. 2018 Dec;206:72-79. doi: 10.1016/j.ahj.2018.07.012. Epub 2018 Aug 2.
4
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.一种复方制剂（Polycap）对无心血管疾病中年个体危险因素的影响（TIPS）：一项II期双盲随机试验。
Lancet. 2009 Apr 18;373(9672):1341-51. doi: 10.1016/S0140-6736(09)60611-5. Epub 2009 Mar 30.
5
Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers.一种新型五成分复方胶囊（polycap）中成分生物利用度的保持和药物相互作用的缺乏：一项在健康志愿者中进行的五臂交叉试验。
Am J Cardiovasc Drugs. 2010;10(2):95-103. doi: 10.2165/11532170-000000000-00000.
6
A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.一项基于复方药丸策略改善高危心血管疾病人群接受既定预防治疗的实用随机试验。
Eur J Prev Cardiol. 2015 Jul;22(7):920-30. doi: 10.1177/2047487314530382. Epub 2014 Mar 27.
7
Reflections on the regulation of the Polypill.关于复方药丸监管的思考。
Nat Clin Pract Cardiovasc Med. 2009 Feb;6(2):94-5. doi: 10.1038/ncpcardio1416. Epub 2008 Dec 2.
8
Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.心血管疾病患者或具有类似高风险的患者从不同治疗方案转换为固定剂量复方药丸（多效药丸）的影响。
Eur J Prev Cardiol. 2017 Jun;24(9):951-961. doi: 10.1177/2047487317695616. Epub 2017 Mar 8.
9
A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization.复方药丸用于心血管疾病一级预防：世界卫生组织的可行性研究。
Trials. 2011 Jan 5;12:3. doi: 10.1186/1745-6215-12-3.
10
Multicap to improve adherence after acute coronary syndromes: results of a randomized controlled clinical trial.多剂量胶囊改善急性冠脉综合征后的依从性：一项随机对照临床试验的结果
Ther Adv Cardiovasc Dis. 2020 Jan-Dec;14:1753944720912071. doi: 10.1177/1753944720912071.

引用本文的文献

1
QbD-steered HPTLC approach for concurrent estimation of six co-administered COVID-19 and cardiovascular drugs in different matrices: greenness appraisal.基于质量源于设计的高效薄层色谱法同时测定不同基质中六种联合使用的新冠病毒疾病和心血管药物：绿色度评估
Sci Rep. 2025 Feb 20;15(1):6252. doi: 10.1038/s41598-024-83692-x.
2
Preventing premature mortality in chronic diseases for South Asians in the UK and beyond.预防英国及其他地区南亚裔人群慢性病的过早死亡。
J R Soc Med. 2009 Nov;102(11):459-63. doi: 10.1258/jrsm.2009.090112.

本文引用的文献

1
Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data.印度急性冠状动脉综合征的治疗与转归（CREATE）：一项登记数据的前瞻性分析
Lancet. 2008 Apr 26;371(9622):1435-42. doi: 10.1016/S0140-6736(08)60623-6.
2
Homocysteine lowering with folic acid and B vitamins in vascular disease.在血管疾病中使用叶酸和B族维生素降低同型半胱氨酸水平
N Engl J Med. 2006 Apr 13;354(15):1567-77. doi: 10.1056/NEJMoa060900. Epub 2006 Mar 12.
3
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
降低胆固醇治疗的疗效与安全性：对他汀类药物14项随机试验中90,056名参与者数据的前瞻性荟萃分析
Lancet. 2005 Oct 8;366(9493):1267-78. doi: 10.1016/S0140-6736(05)67394-1. Epub 2005 Sep 27.
4
Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials.不同降压方案对主要心血管事件的影响：前瞻性设计的随机试验综述结果
Lancet. 2003 Nov 8;362(9395):1527-35. doi: 10.1016/s0140-6736(03)14739-3.
5
Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials.降压药物低剂量联合治疗的价值：354项随机试验分析
BMJ. 2003 Jun 28;326(7404):1427. doi: 10.1136/bmj.326.7404.1427.
6
Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis.他汀类药物对低密度脂蛋白胆固醇、缺血性心脏病和中风的量化影响：系统评价与荟萃分析
BMJ. 2003 Jun 28;326(7404):1423. doi: 10.1136/bmj.326.7404.1423.
7
A strategy to reduce cardiovascular disease by more than 80%.一种将心血管疾病减少80%以上的策略。
BMJ. 2003 Jun 28;326(7404):1419. doi: 10.1136/bmj.326.7404.1419.
8
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.MRC/BHF糖尿病患者使用辛伐他汀降低胆固醇的心脏保护研究：一项随机安慰剂对照试验（涉及5963名糖尿病患者）
Lancet. 2003 Jun 14;361(9374):2005-16. doi: 10.1016/s0140-6736(03)13636-7.
9
Two decades of progress in preventing vascular disease.预防血管疾病二十年的进展。
Lancet. 2002 Jul 6;360(9326):2-3. doi: 10.1016/S0140-6736(02)09358-3.
10
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.抗血小板治疗预防高危患者死亡、心肌梗死和中风的随机试验协作荟萃分析。
BMJ. 2002 Jan 12;324(7329):71-86. doi: 10.1136/bmj.324.7329.71.